Uric acid lowering therapies (UAR) vs placebo: Withdrawals due to adverse events
- Population
- hyperuricaemia in people with hypertension
- Intervention
- Uric acid lowering therapies (UAR)
- Comparison
- placebo
- Outcome
- Withdrawals due to adverse events
Uric acid‐lowering drug showed no clear difference in adverse events (withdrawals due to side effects) compared with placebo (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Uric acid‐lowering drug vs placebo Adverse events (withdrawals due to side effects) · hyperuricaemia in people with hypertension Uric acid‐lowering drug showed no clear difference in adverse events (withdrawals due to side effects) compared with placebo (low certainty). Pharmacotherapy for hyperuricaemia in hypertensive patients (2020) · Cochrane Headline outcomes only | RR 1.86 [0.43, 8.1] | 3 studies · 241 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Pharmacotherapy for hyperuricaemia in hypertensive patients 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Uric acid lowering therapies (UAR) vs placebo · hyperuricemia in hypertensive patients · 0 reviews
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.